Skin reactions after COVID-19 vaccination: Rare, uncommonly recur after second dose

Skin problems such as itchiness, rashes, hives and swelling can occur in some individuals after receiving a COVID-19 vaccine, but it’s not clear how common these reactions are or how frequently they recur with a subsequent vaccination. Research by led by allergists at Massachusetts General Hospital (MGH) now provides encouraging indications that the reactions are rare, and that even when they do occur with an initial COVID-19 vaccination, they seldom recur after receiving a second vaccine dose.

For the study, which is published in JAMA Dermatology, a team led by Kimberly G. Blumenthal, MD, MSc, co-director of the Clinical Epidemiology Program within MGH’s Division of Rheumatology, Allergy and Immunology, prospectively studied 49,197 Mass General Brigham employees who received mRNA COVID-19 vaccines. At least one symptom survey was completed by 40,640 employees after the first dose of vaccine.

Skin reactions were reported by 776 (1.9%) of survey respondents after the first dose. Rash and itching (other than at the injection site) were the most common skin reactions, and the average age of those reporting skin reactions was 41 years. Skin reactions were more common in females (85%) than males (15%) and differed by race (62% white, 7% Black, and 12% Asian).

Among 609 individuals who reported skin reactions to the first dose, received a second dose, and completed a symptom survey after the second dose, 508 (83%) reported no recurrent skin reactions.

Among individuals with no skin reaction to the first dose, 2.3% reported skin reactions after the second dose, with rash and itching being the most common.

Recommended:

---

• View for the Future
• Gabrielle Union, Dwyane Wade to Start Baby Line

---

“This is the first information we have on risk of recurrence of skin reactions after dose 2 when there is a dose 1 reaction. Our findings could provide critical reassurance to people with rashes, hives and swelling after dose 1 of their mRNA vaccines,” says Blumenthal.

Source: Read Full Article